companies / newamsterdampharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-05 json
| total_raised | 453,000,000453.0M | ○ |
|---|---|---|
| founded | 2019 | |
| hq | Amsterdam | |
| industry | unknown | |
| stage | series-b+ |
NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for cardiovascular disease in patients who cannot reach LDL targets on statins alone. Patients with familial hypercholesterolemia and atherosclerotic disease are the target population. The company spun out the program from Amgen and is pursuing Phase 3 clinical readouts.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-12-01 | seed | 453,000,000453.0M | null | ○ |
adobe fonts, cloudflare, cloudflare bot management, google tag manager, http/3, jquery 3.7.1, mysql, php, typekit, wordpress, wp engine, yoast seo 27.7
| fact | status | src |
|---|---|---|
| Seed, $453.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |